chartexchange

MS has plenty of drugs. This Ocrevus veteran sees what’s missing.

Pharma Voice | Oct 26, 2026 8:54 AM EDT

After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching.

Read original article